BRITAIN'S National Institute for Health and Care Excellence (NICE) says it plans to fast-track approval processes for "new highly cost effective therapies" with the aim of making them available up to three months sooner.
The 'lighter touch' process would apply to treatments likely to have a cost per QALY (quality adjusted life year) of up to 10,000.
"By further streamlining our processes we will ensure treatments that clearly offer exceptional value for money will be available to the patients who need them faster than ever before," said NICE ceo Andrew Dillon.
The above article was sent to subscribers in Pharmacy Daily's issue from 17 Oct 16
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 17 Oct 16